Addex Therapeutics Ltd - Asset Resilience Ratio

Latest as of March 2026: 0.05%

Addex Therapeutics Ltd (ADXN) has an Asset Resilience Ratio of 0.05% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See working capital to net assets of Addex Therapeutics Ltd to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

CHF2.35K

≈ $2.97K USD Cash + Short-term Investments

Total Assets

CHF4.76 Million

≈ $6.02 Million USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2017–2025)

This chart shows how Addex Therapeutics Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see total assets of Addex Therapeutics Ltd.

Liquid Assets Composition Over Time

This chart breaks down Addex Therapeutics Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore ADXN long-term investment intensity to see how much of total assets are deployed in long-term investments.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	CHF0.00	0%
Short-term Investments	CHF2.35K	0.05%
Total Liquid Assets	CHF2.35K	0.05%

Asset Resilience Insights

Limited Liquidity: Addex Therapeutics Ltd maintains only 0.05% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

Addex Therapeutics Ltd Industry Peers by Asset Resilience Ratio

Compare Addex Therapeutics Ltd's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
ALK-Abelló A/S CO:ALK-B	Biotechnology	0.98%
Mirum Pharmaceuticals Inc NASDAQ:MIRM	Biotechnology	6.89%
Xiamen Amoytop Biotech Co Ltd SHG:688278	Biotechnology	4.69%
BB Biotech AG SW:BION	Biotechnology	92.97%
Soleno Therapeutics Inc NASDAQ:SLNO	Biotechnology	20.15%
Nanobiotix NASDAQ:NBTX	Biotechnology	4.71%
Wuhan Keqian Biology Co Ltd SHG:688526	Biotechnology	19.42%
Beijing Konruns Pharmaceutical Co Ltd SHG:603590	Biotechnology	10.55%

Annual Asset Resilience Ratio for Addex Therapeutics Ltd (2017–2025)

The table below shows the annual Asset Resilience Ratio data for Addex Therapeutics Ltd.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	0.08%	CHF5.13K ≈ $6.49K	CHF6.36 Million ≈ $8.04 Million	+0.02pp
2024-12-31	0.06%	CHF6.50K ≈ $8.21K	CHF10.67 Million ≈ $13.49 Million	-83.23pp
2023-12-31	83.29%	CHF3.87 Million ≈ $4.89 Million	CHF4.64 Million ≈ $5.87 Million	-0.75pp
2022-12-31	84.04%	CHF6.96 Million ≈ $8.80 Million	CHF8.28 Million ≈ $10.47 Million	-6.91pp
2021-12-31	90.95%	CHF20.50 Million ≈ $25.92 Million	CHF22.54 Million ≈ $28.50 Million	-2.00pp
2020-12-31	92.95%	CHF18.76 Million ≈ $23.72 Million	CHF20.18 Million ≈ $25.52 Million	+78.84pp
2019-12-31	14.11%	CHF4.66 Million ≈ $5.89 Million	CHF33.03 Million ≈ $41.76 Million	+14.09pp
2018-12-31	0.02%	CHF7.98K ≈ $10.09K	CHF42.21 Million ≈ $53.37 Million	-0.35pp
2017-12-31	0.37%	CHF11.29K ≈ $14.27K	CHF3.06 Million ≈ $3.87 Million	--

pp = percentage points

About Addex Therapeutics Ltd

SW:ADXN Switzerland Biotechnology

Market Cap

$4.26 Million

CHF3.37 Million CHF

Market Cap Rank

#29147 Global

#213 in Switzerland

Share Price

CHF0.02

Change (1 day)

-0.89%

52-Week Range

CHF0.02 - CHF0.07

All Time High

CHF3.90